TrialScope’s Board of Directors oversees our leaders and works with the team to set the direction for TrialScope to excel as a clinical transparency leader.

Mark Heinold

Mark Heinold

CEO, TrialScope

Mark has spent over 20 years in the pharmaceutical, healthcare services and healthcare information technology sectors. In his most recent role, Mark served as the CEO of Physicians’ Desk Reference (PDR), the iconic multi-media source for prescription drug labels.

Prior to joining PDR, Mark served as the CEO of LDM Group, a leading provider of targeted clinically relevant communications to prescribers, pharmacists and patients.  Mark led a team which successfully integrated the businesses of PDR and LDM, resulting in the rapid sale of the merged company to new private equity owners.

Prior to LDM Group, Mark held the position of National Vice President of Sales and Operations for Catalina Marketing Corporation, where he greatly increased the revenues achieved from targeted, behavior based, patient messaging at the pharmacy point of sale.  Mark began his career at Novartis, where he held various executive leadership positions in marketing, sales, and operations over the course of ten years.

Mark holds a BA in Business Administration and Communications from Seton Hall University and an MBA from the Columbia Business School at Columbia University.

Michael Balmuth

Michael Balmuth

General Partner, Edison Ventures

Michael has more than 25 years of technology industry experience as a venture capitalist, investment banker and software executive. He currently leads Edison Ventures’ industry sector practice in healthcare information technology and heads the firm’s New England team based in Boston.

Before Edison, he served as Managing Partner of Mainspring Capital and General Partner at Summit Partners. At Summit, he led the East Coast office of Summit Venture Capital Fund as a founding partner.  Previously, Michael worked in technology investment banking with Broadview International. His early career at IBM Corporation spanned sales, marketing, corporate development and systems engineering. Michael has served as a Director of numerous public and private companies.  Prior investments, all of which exited at gains through an IPO or strategic M&A include: Infor; Unica; OPNET; MCK Communications; Future Three; InstallShield; Microbank; PowerSmart; Staples.com; TrelliSoft. Michael holds a BA, Engineering Sciences from Dartmouth College and an MBA from Harvard Business School.

Chris Noe

Chris Noe

General Partner, Dublin Capital Partners

Christopher Noe is general partner of Dublin Capital Partners, a Lenfest affiliated fund, which invests in digital media, software and technology enabled service businesses. Mr. Noe previously led the turnaround and growth of three different Lenfest owned businesses, two of which were successfully sold to OpenTV and one that is still held by the Lenfest family.

Prior to working for the Lenfest family, Mr. Noe was a managing director with Katalyst, a venture fund and private equity services firm focused on the cable and information technology industries. He has held leadership positions in sales, business development, and consulting with IBM and Computer Sciences Corporation. He started his career in public accounting with KPMG. He currently serves on the board of directors for Broadway Systems, Iron Solutions, XOS Digital, Zixi, and TrialScope. Mr. Noe attained a Bachelor of Science degree in business administration and accounting from the University of Connecticut and earned his certification as a public accountant in the state of Connecticut (since expired).

Charles Saldarini

Charles Saldarini

Managing Partner, VoteTocracy

A proven leader, Chuck has a successful track record that spans all phases of organizational growth from start-up to turnaround. For over 25 years, he has provided emerging companies with executive leadership and consulting services covering commercial readiness, enterprise strategy and structure, and business development.

Most recently, Chuck served as Managing Partner for VoteTocracy, a Webby 2014 honoree. VoteTocracy is a political engagement website enabling citizens to vote on any bill presently pending in the U.S. Congress. Previously, he served as interim Executive VP of Octagon Clinical Research Solutions, where he led Global Business Development and supported the process and negotiation for its sale to Accenture. Chuck also led the turnaround of Sentrx serving as CEO and Vice Chairman. Most notably, Chuck led PDI, Inc. from its inception in 1987 to peak revenues of $365M, including a successful IPO in 1998, helping PDI earn a reputation as a premier provider of outsourced sales and marketing services. When not working or volunteering on one of several Executive Boards including TrialScope, a Software as a Service (SaaS) business, and RPS, a rapid pathogen screening company with point of care diagnostic solutions, Chuck is still on the move, actively competing in several triathlons each year. He earned his B.A. with honors from Syracuse University.

Jeff Kozloff

Jeff Kozloff

Co-founder and former CEO of Verilogue

Jeff Kozloff is the co-founder and former CEO of Verilogue, which he ran until the company's acquisition by Publicis (PUB:FP). Verilogue is the global leader in the capture and analysis of physician-patient dialogue and associated communication studies.

The company’s unique methods and linguistic analytics are cited in prestigious peer-reviewed medical journals.  Before joining TrialScope, Mr. Kozloff also served on the Board of Directors for iContracts, a venture-backed software company specializing in healthcare document and payment automation.  Jeff holds a degree from the Wharton School and is the co-author of a method and system patent for analyzing the effectiveness of marketing strategies.

Jim Walker

Jim Walker

Founder, Octagon Research Solutions, Inc.

James C. Walker has been working in the pharmaceutical industry for 20 years. He is the founder of Octagon Research Solutions, Inc. Prior to founding Octagon, he worked as the Senior Manager of Worldwide Regulatory Affairs for the Schering-Plough Corporation (“Schering”).

While at Schering, he was responsible for clinical and pre-clinical in the antihistamine, central nervous system, and critical care therapeutic areas.

Prior to joining Schering, Mr. Walker worked across multiple therapeutic areas in the Regulatory Affairs/Clinical and Clinical Quality Assurance department at the R.W. Johnson Pharmaceutical Research Institute (PRI). Mr. Walker has extensive experience in and knowledge of all phases of clinical research and both FDA and European regulations. He is skilled at process improvement and providing insight across multiple disciplines within drug development. Mr. Walker holds a B.S. in Biological Sciences from Villanova University, a Masters in Environmental Sciences from Rutgers University, and an M.B.A. from Duke University.